Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more
Market Cap & Net Worth: Zealand Pharma A/S (ZLDPF)
Zealand Pharma A/S (PINK:ZLDPF) has a market capitalization of $4.36 Billion ($4.36 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3615 globally and #2350 in its home market, demonstrating a -24.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zealand Pharma A/S's stock price $61.95 by its total outstanding shares 70437463 (70.44 Million).
Zealand Pharma A/S Market Cap History: 2015 to 2025
Zealand Pharma A/S's market capitalization history from 2015 to 2025. Data shows growth from $1.53 Billion to $4.36 Billion (10.11% CAGR).
Zealand Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zealand Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
116.91x
Zealand Pharma A/S's market cap is 116.91 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.53 Billion | $187.68 Million | -$113.96 Million | 8.15x | N/A |
| 2016 | $1.16 Billion | $234.78 Million | -$153.91 Million | 4.95x | N/A |
| 2017 | $968.52 Million | $139.78 Million | -$272.27 Million | 6.93x | N/A |
| 2018 | $852.30 Million | $37.98 Million | $581.28 Million | 22.44x | 1.47x |
| 2019 | $2.48 Billion | $41.33 Million | -$571.54 Million | 59.90x | N/A |
| 2020 | $2.53 Billion | $353.31 Million | -$846.73 Million | 7.17x | N/A |
| 2021 | $1.55 Billion | $292.57 Million | -$1.02 Billion | 5.31x | N/A |
| 2022 | $1.98 Billion | $103.99 Million | -$965.61 Million | 19.09x | N/A |
| 2023 | $3.92 Billion | $342.79 Million | -$703.74 Million | 11.44x | N/A |
| 2024 | $7.33 Billion | $62.69 Million | -$1.08 Billion | 116.91x | N/A |
Competitor Companies of ZLDPF by Market Capitalization
Companies near Zealand Pharma A/S in the global market cap rankings as of March 18, 2026.
Key companies related to Zealand Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Zealand Pharma A/S Historical Marketcap From 2015 to 2025
Between 2015 and today, Zealand Pharma A/S's market cap moved from $1.53 Billion to $ 4.36 Billion, with a yearly change of 10.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.36 Billion | -40.46% |
| 2024 | $7.33 Billion | +86.97% |
| 2023 | $3.92 Billion | +97.48% |
| 2022 | $1.98 Billion | +27.86% |
| 2021 | $1.55 Billion | -38.69% |
| 2020 | $2.53 Billion | +2.28% |
| 2019 | $2.48 Billion | +190.49% |
| 2018 | $852.30 Million | -12.00% |
| 2017 | $968.52 Million | -16.67% |
| 2016 | $1.16 Billion | -24.03% |
| 2015 | $1.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Zealand Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.36 Billion USD |
| MoneyControl | $4.36 Billion USD |
| MarketWatch | $4.36 Billion USD |
| marketcap.company | $4.36 Billion USD |
| Reuters | $4.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.